Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

The Role of Cysteamine Dioxygenase (ADO) in the Hepatocellular Carcinoma Tumor Immune Microenvironment

EF 2025-26

Résumé
A type of liver cancer, called hepatocellular carcinoma (HCC), is one of the deadliest cancers worldwide. Even with surgery, chemotherapy, and new targeted drugs, most patients eventually experience relapse or limited response to treatment. One major reason is that liver tumors create a hostile environment that prevents the immune system from recognizing and attacking cancer cells. Understanding what drives this immune suppression could reveal new ways to make existing treatments more effective. Our research focuses on an enzyme called 2-aminoethanethiol dioxygenase (ADO), which is involved in how cells metabolize an amino acid called cysteine. Early evidence suggests that ADO may influence how immune cells behave inside the tumour, and a commonly used blood-pressure medication, hydralazine, can block ADO activity. Interestingly, patients taking hydralazine sometimes develop increased immune activity, suggesting that ADO inhibition could strengthen anti-cancer immunity. To explore this, we will use laboratory and mouse models of HCC to study how the tumors change when ADO is removed or reduced. We will examine which immune cells enter the tumor, how active they are, and whether blocking ADO with hydralazine improves the immune system’s ability to attack cancer cells. We will also use techniques such as flow cytometry and gene expression analysis to build a detailed picture of how ADO shapes the tumour environment. By uncovering how ADO connects metabolism and immune function in liver cancer, this project aims to provide insights that could guide the development of new treatment strategies, including the potential use of hydralazine, to improve outcomes for patients facing this aggressive disease.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572607
Name
Liu Yuxin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Cysteamine Dioxygenase (ADO) in the Hepatocellular Carcinoma Tumor Immune Microenvironment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
2-Aminoethanethiol Dioxygenase (Ado); Hepatocellular Carcinoma; Tumor Immune Microenvironment
Abstract
A type of liver cancer, called hepatocellular carcinoma (HCC), is one of the deadliest cancers worldwide. Even with surgery, chemotherapy, and new targeted drugs, most patients eventually experience relapse or limited response to treatment. One major reason is that liver tumors create a hostile environment that prevents the immune system from recognizing and attacking cancer cells. Understanding what drives this immune suppression could reveal new ways to make existing treatments more effective. Our research focuses on an enzyme called 2-aminoethanethiol dioxygenase (ADO), which is involved in how cells metabolize an amino acid called cysteine. Early evidence suggests that ADO may influence how immune cells behave inside the tumour, and a commonly used blood-pressure medication, hydralazine, can block ADO activity. Interestingly, patients taking hydralazine sometimes develop increased immune activity, suggesting that ADO inhibition could strengthen anti-cancer immunity. To explore this, we will use laboratory and mouse models of HCC to study how the tumors change when ADO is removed or reduced. We will examine which immune cells enter the tumor, how active they are, and whether blocking ADO with hydralazine improves the immune system’s ability to attack cancer cells. We will also use techniques such as flow cytometry and gene expression analysis to build a detailed picture of how ADO shapes the tumour environment. By uncovering how ADO connects metabolism and immune function in liver cancer, this project aims to provide insights that could guide the development of new treatment strategies, including the potential use of hydralazine, to improve outcomes for patients facing this aggressive disease.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liu, Yuxin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~